Hairy Cell Leukemia
📧 Sign up to get email alerts when something new happens for Hairy Cell Leukemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-04-03EMA Authorised: Litak (cladribine) — Lipomed GmbH
The European Medicines Agency authorized Litak, a cladribine product from Lipomed GmbH, for hairy cell leukemia.
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
A completed clinical trial investigated the role of large extracellular vesicles as biomarkers in various lymphomas and lymphoproliferative …
-
CLINICAL_TRIALS research · 2025-01-17Clinical Trial Update: Assessment of Disease Burden in Hairy Cell Leukemia [NA]
A clinical trial is assessing disease burden in hairy cell leukemia and is currently recruiting at a sponsor site.
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management
A clinical trial investigating how extracellular vesicles mediate communication in the microenvironment of Hairy Cell Leukemia to improve pa…
-
CLINICAL_TRIALS research · 2025-01-08Clinical Trial Update: Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management
A clinical trial investigating extracellular vesicle-based strategies for Hairy cell leukemia is currently recruiting. The study aims to har…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab [Phase 2]
This update reports the results of a Phase 2 trial evaluating the combination of cladribine and rituximab for hairy cell leukemia and its va…
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: Therapy Optimisation for the Treatment of Hairy Cell Leukemia [Phase 2, Phase 3]
A clinical trial update for therapy optimisation in hairy cell leukemia is in Phase 2/3 and currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
A long-term follow-up update on patients previously treated with Mustang Bio's CAR-T cell investigational product; the trial has been termin…
-
CLINICAL_TRIALS trial_result · 2024-05-01Clinical Trial Update: Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia [Phase 2]
A randomized Phase II trial comparing rituximab plus pentostatin versus rituximab plus bendamustine in multiply relapsed or refractory hairy…
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia [Phase 1]
Phase 1 trial evaluating moxetumomab pasudotox-tdfk (Lumoxiti) in combination with either rituximab (Rituxan) or the rituximab biosimilar Ru…
-
EMA withdrawal · 2021-08-11EMA Withdrawn: Lumoxiti (moxetumomab pasudotox) — AstraZeneca AB
Lumoxiti (moxetumomab pasudotox) has been withdrawn from use in the European market.
-
FDA approval · 2019-10-28FDA Approved: NIPENT — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for Nipent (pentostatin) submitted by Hospira, Inc., approving the requested supplemental change to …
-
CLINICAL_TRIALS trial_result · 2019-04-05Clinical Trial Update: LMB-2 to Treat Hairy Cell Leukemia [Phase 2]
Phase 2 trial update for LMB-2 in hairy cell leukemia; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-04-02Clinical Trial Update: A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia [Phase 1]
Phase I multicenter dose-escalation study in patients with Hairy Cell Leukemia completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2018-08-27Clinical Trial Update: Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia [Phase 3]
Phase 3 trial update for moxetumomab pasudotox in advanced hairy cell leukemia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-07-19Clinical Trial Update: Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
This Clinical Trial Update describes a study collecting and storing malignant and related samples from young cancer patients; the trial stat…
-
CLINICAL_TRIALS trial_result · 2017-08-11Clinical Trial Update: Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease
The clinical trial evaluated the BRAF V600E mutation status in chronic lymphoproliferative diseases, specifically hairy cell leukemia and sp…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab in patients undergoing donor peripheral blood stem cell transplantation for relapsed or refractory B-cell…
-
CLINICAL_TRIALS research · 2016-08-30Clinical Trial Update: Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study
A multicenter retrospective study evaluates the use of rituximab in hairy cell leukemia.
-
FDA approval · 2015-12-29FDA Approved: NIPENT — Supplemental Application (Hospira, Inc.)
The FDA approved a supplemental application for Nipent (pentostatin) from Hospira.
-
CLINICAL_TRIALS trial_result · 2015-04-29Clinical Trial Update: Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia [Phase 1]
The document provides an update on the completion of a Phase 1 clinical trial evaluating immunotoxin therapy in patients with hairy cell leu…
-
FDA approval · 2013-06-20FDA Approved: NIPENT — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for Nipent (pentostatin) submitted by Hospira, Inc.
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma [Phase 1]
Phase 1 study evaluating a combination of alvocidib, fludarabine phosphate, and rituximab in various B-cell lymphoproliferative disorders, w…
-
FDA approval · 2013-01-08FDA Approved: CLADRIBINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Cladribine from Hikma Pharmaceuticals USA Inc.
-
CLINICAL_TRIALS trial_result · 2012-05-15Clinical Trial Update: Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia [Phase 3]
A Phase 3 trial evaluating daily versus weekly dosing of cladribine for hairy cell leukemia has completed, reporting results on dosing sched…